Does Rallies show 13F holders for EXAS?

Yes. Rallies tracks hedge fund and 13F ownership data for EXAS, including fund names, share counts, latest tracked quarter, and position changes when available.

Is EXAS research on Rallies investment advice?

No. Rallies provides research, data, and educational context for EXAS. It does not provide personalized investment advice.

EXAS (Exact Sciences Corp) Stock Analysis - Hedge Fund Holdings

Exact Sciences Corp (EXAS) is a publicly traded Healthcare sector company. As of May 21, 2026, EXAS trades at $104.91 with a market cap of $20.03B and a P/E ratio of -95.37. EXAS moved -0.02% today. Year to date, EXAS is +56.63%; over the trailing twelve months it is +136.92%. Its 52-week range spans $38.81 to $104.98. Analyst consensus is buy with an average price target of $103.18. Rallies surfaces EXAS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns EXAS stock?

Hedge funds tracked by Rallies that own EXAS include Pentwater Capital, Farallon Capital, Davidson Kempner, Soros Fund, and Glenview Capital. The latest tracked quarter is Dec 31, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Exact Sciences Corp.

EXAS Key Metrics

Key financial metrics for EXAS
Metric	Value
Price	$104.91
Market Cap	$20.03B
P/E Ratio	-95.37
EPS	$-1.10
Dividend Yield	0.00%
52-Week High	$104.98
52-Week Low	$38.81
Volume	21.56M
Avg Volume	0
Revenue (TTM)	$3.25B
Net Income	$-207.95M
Gross Margin	69.69%

Top Hedge Funds Holding EXAS

Pentwater Capital holds 7.25M shares of EXAS, changed +0.00% as of Dec 31, 2025.
Farallon Capital holds 6.41M shares of EXAS, changed +0.00% as of Dec 31, 2025.
Davidson Kempner holds 4.23M shares of EXAS, changed +0.00% as of Dec 31, 2025.
Soros Fund holds 864.01K shares of EXAS, changed +73.87% as of Dec 31, 2025.
Glenview Capital holds 629.46K shares of EXAS, changed +176.60% as of Jun 30, 2024.

Latest EXAS News

Abbott Finalizes $23 Billion Exact Sciences Acquisition to Control Cologuard Tests — Mar 24, 2026
Exact Sciences Posts Forward P/E 71.29 and Wins Third Gallup Workplace Award — Mar 4, 2026
Quanterix Q4 revenue jumps 25% to $43.9M, places 38 instruments — Mar 2, 2026
Exact Sciences Shareholders Approve Abbott Merger, Reject Executive Pay Plan — Feb 23, 2026
Exact Sciences Stockholders Approve Abbott Acquisition with Over 80% Vote — Feb 20, 2026

Recent EXAS Insider Trades

ORVILLE JACOB A sold 5.00K (~$375.00K) on Nov 19, 2025.
Herriott James sold 1.00K (~$70.00K) on Nov 19, 2025.
Herriott James sold 1.50K (~$105.12K) on Nov 4, 2025.

EXAS Analyst Consensus

41 analysts cover EXAS: 0 strong buy, 22 buy, 17 hold, 2 sell, 0 strong sell. Consensus rating is buy. Average price target: $103.18.

Common questions about EXAS

Who owns EXAS stock?: Hedge funds tracked by Rallies that own EXAS include Pentwater Capital, Farallon Capital, Davidson Kempner, Soros Fund, and Glenview Capital. The latest tracked quarter is Dec 31, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Exact Sciences Corp.
Does Rallies show 13F holders for EXAS?: Yes. Rallies tracks hedge fund and 13F ownership data for EXAS, including fund names, share counts, latest tracked quarter, and position changes when available.
Is EXAS research on Rallies investment advice?: No. Rallies provides research, data, and educational context for EXAS. It does not provide personalized investment advice.